Volume 6, Number 4—August 2000
Research
Reemergence of Pertussis in the Highly Vaccinated Population of The Netherlands: Observations on Surveillance Data
Hester E. de Melker
, J.F.P. Schellekens, S.E. Neppelenbroek, F.R. Mooi, H.C. Rümke, and M.A.E. Conyn-van Spaendonck
, J.F.P. Schellekens, S.E. Neppelenbroek, F.R. Mooi, H.C. Rümke, and M.A.E. Conyn-van Spaendonck
Table 1
Reported cases, hospitalizations, ratios of reported cases to hospitalizations, positive 2-point serology and positive 1-point serology, 1976-1998
| Yr | Reports | Hosps | Pos, 2-point test | Pos, 1-point test | Ratio of reports/hosps | Ratio of reports/pos.2-point test | Ratio of reports/pos.1-point test |
|---|---|---|---|---|---|---|---|
| 1976a | 4 | 52 | NA | NA | 0.1 | NA | NA |
| 1977 | 25 | 93 | NA | NA | 0.3 | NA | NA |
| 1978 | 1 | 32 | NA | NA | 0.0 | NA | NA |
| 1979 | 26 | 43 | NA | NA | 0.6 | NA | NA |
| 1980 | 30 | 65 | NA | NA | 0.5 | NA | NA |
| 1981b | 50 | 76 | NA | NA | 0.7 | NA | NA |
| 1982 | 80 | 98 | NA | NA | 0.8 | NA | NA |
| 1983 | 200 | 223 | NA | NA | 0.9 | NA | NA |
| 1984c | 534 | 200 | NA | NA | 2.7 | NA | NA |
| 1985 | 1522 | 313 | NA | NA | 4.9 | NA | NA |
| 1986 | 2159 | 388 | NA | 2717 | 5.6 | NA | 0.8 |
| 1987 | 2709 | 474 | NA | 3295 | 5.7 | NA | 0.8 |
| 1988d | 112 | 92 | NA | NA | 1.2 | NA | NA |
| 1989 | 523 | 221 | 350 | 1760 | 2.4 | 1.5 | 0.3 |
| 1990 | 397 | 157 | 278 | 1204 | 2.5 | 1.4 | 0.3 |
| 1991 | 145 | 82 | 110 | 411 | 1.8 | 1.3 | 0.4 |
| 1992 | 160 | 101 | 238 | 861 | 1.6 | 0.7 | 0.2 |
| 1993 | 346 | 288 | 482 | 1489 | 1.2 | 0.7 | 0.2 |
| 1994 | 519 | 276 | 498 | 1867 | 1.9 | 1.0 | 0.3 |
| 1995 | 341 | 162 | 272 | 1070 | 2.1 | 1.3 | 0.3 |
| 1996 | 4231 | 513 | 1885 | 7854 | 8.2 | 2.2 | 0.5 |
| 1997e | 2671 | 436 | 924 | 4107 | 6.1 | 2.9 | 0.7 |
| 1998f | 1582 | NA | 294 | 2187 | NA | 5.4 | 0.7 |
aMandatory case reporting introduced.
bIgA assay introduced.
cIgG assay introduced.
dCase definition for reporting (including strict criteria for interpretation of serologic tests) introduced.
eFormal acceptance of positive one-point serologic test.
fData from January to September 1998.
1-point test = cases with one-point serology; 2-point test = cases with two-point serology; NA=not available.
1Vaccine effectiveness = 1 – (proportion of vaccinated cases/1 – proportion of vaccinated cases) X (1 – proportion vaccinated in the population/proportion vaccinated in the population).
Page created: December 16, 2010
Page updated: December 16, 2010
Page reviewed: December 16, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.